CALR and myeloproliferative neoplasm: Although there were no significant differences in leukocyte count, hemoglobin level, and CALR mutant burden, the median platelet count was significantly higher in patients who had MPN with type 2-like CALR mutation than in those with type 1-like CALR mutation (892 × 109/L vs. 491 × 109/L, p < 0.001); similarly, ET seemed to be more frequent than PMF (79% vs. 21%, p = 0.051) in those with type 2-like CALR mutation.